<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650754</url>
  </required_header>
  <id_info>
    <org_study_id>CHR2008 1.0</org_study_id>
    <nct_id>NCT00650754</nct_id>
  </id_info>
  <brief_title>Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility</brief_title>
  <acronym>DHEAFert</acronym>
  <official_title>A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Normal Hysterosalpingogram and Normal Semen Analysis and Evidence of Premature Ovarian Aging (POA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Human Reproduction</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Human Reproduction</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The experimental focus of this project is on the interaction of DHEA treatment on pregnancy&#xD;
      in women with otherwise unexplained infertility and evidence of premature ovarian aging&#xD;
      (POA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment:&#xD;
&#xD;
      Eligible patients will be recruited by advertising on the web and in newspaper. We will&#xD;
      screen women under 38 years old with regular menstrual cycles and more than one year of&#xD;
      infertility.&#xD;
&#xD;
      Experimental plan:&#xD;
&#xD;
        1. Informed consent&#xD;
&#xD;
        2. Baseline studies&#xD;
&#xD;
             -  Antral follicle counts on Day 2 - 3 of cycle&#xD;
&#xD;
             -  Day 3 Serum FSH, LH, E2, Prog, DHEA, DHEAS, testosterone, AMH, Fragile X&#xD;
&#xD;
        3. Randomization for pretreatment&#xD;
&#xD;
             -  Group A: DHEA (25 mg three times per day)&#xD;
&#xD;
             -  Group B: Placebo&#xD;
&#xD;
        4. Monitoring during treatment&#xD;
&#xD;
             -  All participants will have:&#xD;
&#xD;
             -  USG for follicle measurement&#xD;
&#xD;
             -  Repeat serum, FSH, E2, DHEA, DHEAS, testosterone, AMH monthly during treatment.&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
             -  Completion of study questionnaire regarding possible androgen effects of treatment&#xD;
&#xD;
        5. Analysis plan:&#xD;
&#xD;
             -  Primary Outcome&#xD;
&#xD;
             -  Pregnancy&#xD;
&#xD;
             -  Pregnancy rates will be compared using logistic regression with age and&#xD;
                pre-treatment AMH as covariates.&#xD;
&#xD;
             -  Secondary Outcomes&#xD;
&#xD;
             -  Endocrine Factors&#xD;
&#xD;
             -  Androgen side effects&#xD;
&#xD;
             -  Primary analysis. We will perform a factorial ANOVA for the two pretreatment&#xD;
                factors DHEA and Placebo. Baseline AMH and age as main covariates&#xD;
&#xD;
             -  Secondary analysis.&#xD;
&#xD;
             -  Examine rate of change of estradiol and other endocrine response over the four&#xD;
                cycles of pretreatment&#xD;
&#xD;
             -  Compare antral follicle counts across pretreatment cycles between groups&#xD;
&#xD;
             -  Compare possible androgen related effects&#xD;
&#xD;
             -  Power considerations:&#xD;
&#xD;
             -  Power assumptions: alpha 0.05; 80% power&#xD;
&#xD;
             -  Pregnancy rate for unexplained infertility is 2% per cycle.&#xD;
&#xD;
             -  Intervention will improve pregnancy rate to 5% per cycle.&#xD;
&#xD;
             -  Patients will be treated for 8 cycles.&#xD;
&#xD;
             -  Cumulative pregnancy rate for control patients - 13%&#xD;
&#xD;
             -  Cumulative pregnancy rate for Treated patients - 30%&#xD;
&#xD;
             -  Require 91 patients to complete treatment in each group.&#xD;
&#xD;
             -  Allow for 20% dropout ( 91* 1.2) will need 109 patients randomized to each group.&#xD;
&#xD;
             -  Randomization:&#xD;
&#xD;
      Randomization will be by permuted blocks in order to maintain an even distribution among the&#xD;
      groups (because of the small numbers of participants)&#xD;
&#xD;
        -  Human subjects issues&#xD;
&#xD;
        -  Potential risks associated with DHEA use&#xD;
&#xD;
        -  Potential risk of delay of treatment for 8 months and possible natural continued loss of&#xD;
           fertility&#xD;
&#xD;
        -  Informed consent issues&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit designed nuimebrt of subjects&#xD;
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endocrine effects</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen side effects</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <condition>Unexplained Infertility</condition>
  <arm_group>
    <arm_group_label>DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dehydroepiandrosterone</intervention_name>
    <description>25 mg PO TID</description>
    <arm_group_label>DHEA</arm_group_label>
    <other_name>DHEA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;= 1 year of infertility&#xD;
&#xD;
          -  &lt; 38 years old&#xD;
&#xD;
          -  Normal HSG&#xD;
&#xD;
          -  Normal Semen analysis (Count &gt;= 20 million/ motility &gt; 50%/ Kruger morph &gt; 14%.&#xD;
&#xD;
          -  Regular menses&#xD;
&#xD;
          -  Willingness to sign informed consent for study randomization&#xD;
&#xD;
          -  Willingness to participate in 8 months of non-IVF will he him treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal semen analysis&#xD;
&#xD;
          -  Abnormal HSG&#xD;
&#xD;
          -  Baseline FSH/E2 within normal age specific criteria&#xD;
&#xD;
          -  Medical condition that would contraindicate pregnancy, ovulation induction or general&#xD;
             anesthesia&#xD;
&#xD;
          -  Family history of significant genetic disease, or factor V leiden thrombophilia&#xD;
&#xD;
          -  Inability to present for monitoring visits&#xD;
&#xD;
          -  Inability to follow medication instruction&#xD;
&#xD;
          -  Desire to undergo other fertility treatments before completing eight months of this&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Barad, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Gleicher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Reproduction</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.centerforhumanreprod.com/</url>
    <description>Center for Human Reproduction</description>
  </link>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DHEA</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

